# A Study of PF-07260437 in Advanced or Metastatic Solid Tumors

> **NCT05067972** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 30 (actual)

## Conditions studied

- Ovarian Neoplasms
- Endometrial Neoplasms
- Breast Neoplasms

## Interventions

- **DRUG:** PF-07260437
- **DIAGNOSTIC_TEST:** B7-H4 IHC

## Key facts

- **NCT ID:** NCT05067972
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-07
- **Primary completion:** 2023-10-17
- **Final completion:** 2023-10-17
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities.
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067972, "A Study of PF-07260437 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05067972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*